Выбор редакции

NeuroDerm Skyrockets on Parkinson's Disease Study Data - Analyst Blog

NeuroDerm (NDRM) announced encouraging top-line data from a phase IIa pharmacokinetic study on its levodopa/carbidopa candidates, ND0612H and ND0612L.

НОВОСТИ ПО ТЕМЕ